---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-256538"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:26:48.139607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium presents pre-clinical data for oral EQ302 targeting IL-15/IL-21; analysts day held

## Summary
- EQ302 is an orally deliverable multi-cytokine inhibitor targeting IL-15 and IL-21.
- Pre-clinical data show hydrocarbon staples improve GI stability while retaining cytokine inhibition.
- Oral EQ302 reduced IL-15-induced IFN-g transcription in mouse small intestine.
- Potential utility for Celiac Disease and inflammatory bowel disease highlighted.
- Analyst and investor day held October 16, 2023, with pipeline and platform update.

## SEC filing metadata
- accession: 0001193125-23-256538
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/0001193125-23-256538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/d500418d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-256538
- JSON: https://secwatch.observer/filing/0001193125-23-256538.json
- Plain text: https://secwatch.observer/filing/0001193125-23-256538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.